Meeting
2018 ASCO Annual Meeting
Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials.
Authors
Shiraj Sen
The University of Texas Southwestern Medical School, Dallas, TX
Shiraj Sen , Kenneth R. Hess , David S. Hong , Aung Naing , Le Huang , Funda Meric-Bernstam , Vivek Subbiah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3077)
DOI
10.1200/JCO.2018.36.15_suppl.3077
Abstract #
3077
Poster Bd #
291
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association between physical activity, immune-related adverse events, and mortality in patients undergoing immune checkpoint inhibition.
First Author: Rik Jasper Verheijden
Poster
2020 ASCO Virtual Scientific Program
Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.
First Author: Richard Lee O'Neal
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I trial combining plinabulin and nivolumab for metastatic NSCLC: Trial in progress.
First Author: Nicolas Villanueva
Poster
2024 ASCO Annual Meeting
A phase I open-label study of a novel IL-2Rβ/γ cytokine agonist, LTC004, in patients with advanced or metastatic solid tumors.
First Author: Jifang Gong